Moody Aldrich Partners LLC boosted its position in Natus Medical Inc (NASDAQ:BABY) by 74.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 68,217 shares of the medical equipment provider’s stock after buying an additional 29,190 shares during the period. Moody Aldrich Partners LLC owned approximately 0.20% of Natus Medical worth $2,353,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. SG Americas Securities LLC purchased a new stake in shares of Natus Medical during the 1st quarter worth $124,000. US Bancorp DE boosted its position in shares of Natus Medical by 81.2% during the 1st quarter. US Bancorp DE now owns 4,742 shares of the medical equipment provider’s stock worth $159,000 after purchasing an additional 2,125 shares in the last quarter. Sei Investments Co. boosted its position in shares of Natus Medical by 46.3% during the 2nd quarter. Sei Investments Co. now owns 4,669 shares of the medical equipment provider’s stock worth $161,000 after purchasing an additional 1,478 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Natus Medical by 1,010.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,132 shares of the medical equipment provider’s stock worth $177,000 after purchasing an additional 4,670 shares in the last quarter. Finally, Xact Kapitalforvaltning AB purchased a new stake in shares of Natus Medical during the 2nd quarter worth $201,000. Hedge funds and other institutional investors own 96.88% of the company’s stock.

Several equities research analysts have commented on the stock. BidaskClub upgraded shares of Natus Medical from a “hold” rating to a “buy” rating in a research report on Tuesday, June 19th. ValuEngine upgraded shares of Natus Medical from a “sell” rating to a “hold” rating in a research report on Saturday, July 28th. Finally, Zacks Investment Research upgraded shares of Natus Medical from a “sell” rating to a “hold” rating in a research report on Friday, August 10th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $44.33.

In other news, Director Ken Ludlum sold 8,000 shares of the business’s stock in a transaction dated Thursday, August 2nd. The stock was sold at an average price of $36.89, for a total transaction of $295,120.00. Following the completion of the sale, the director now owns 98,957 shares in the company, valued at approximately $3,650,523.73. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jonathan Kennedy sold 47,600 shares of the business’s stock in a transaction dated Thursday, August 30th. The stock was sold at an average price of $36.85, for a total value of $1,754,060.00. Following the sale, the insider now owns 161,628 shares of the company’s stock, valued at approximately $5,955,991.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 77,540 shares of company stock valued at $2,804,615. Corporate insiders own 5.50% of the company’s stock.

Shares of NASDAQ:BABY traded up $0.14 during midday trading on Friday, hitting $32.01. 248,818 shares of the stock were exchanged, compared to its average volume of 348,321. Natus Medical Inc has a twelve month low of $28.00 and a twelve month high of $43.60. The company has a market capitalization of $1.19 billion, a PE ratio of 22.08 and a beta of 0.59. The company has a quick ratio of 2.19, a current ratio of 2.99 and a debt-to-equity ratio of 0.29.

Natus Medical (NASDAQ:BABY) last announced its earnings results on Wednesday, July 25th. The medical equipment provider reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.09. Natus Medical had a negative net margin of 4.16% and a positive return on equity of 11.18%. The firm had revenue of $130.70 million during the quarter, compared to the consensus estimate of $130.60 million. During the same quarter in the previous year, the company posted $0.34 EPS. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. As a group, equities analysts anticipate that Natus Medical Inc will post 1.55 earnings per share for the current year.

About Natus Medical

Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Recommended Story: How Do You Make Money With Penny Stocks?

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.